+ T cell dysfunction and induced a highly proliferative precursor effector memory T cell phenotype in a CD226-dependent manner. PD-1 inhibition rescued CD226 activity by preventing PD-1-Src homology region 2 (SHP2) dephosphophorylation of the CD226 intracellular domain, whereas GITR agonism decreased TIGIT expression. Unmasking the molecular pathways driving durable antitumor responses will be essential to the development of rational approaches to optimizing cancer immunotherapy.
INTRODUCTION
After the initial clinical successes obtained using programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) antibody (Ab) treatments in patients with cancer, the number of immunotherapy agents in clinical development is expanding rapidly with goals of improving the limited response rate and generating more durable responses (1, 2) . Recent elegant studies using infectious disease-related mouse models demonstrated that PD-1 blockade induces an incomplete rescue of exhausted T cells (T Exs ), thus failing to restore T Exs into T effector memory cells (T EMs ), which are required for an effective immune memory (3, 4) . Although PD-1 and/or programmed cell death ligand 1 (PD-L1) inhibition affects the transcriptional and epigenetic landscape of T Exs , these cells are not fully reprogrammed when antigen concentration remains high and fail to acquire a memory phenotype upon antigen clearance (3) . Designing additional strategies to induce more robust T cell activation and/or target other immunoregulatory pathways could contribute to the generation of sustainable long-term responses.
Combination treatments aimed at PD-1 inhibition and activation of costimulatory receptor GITR [glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein or TNFRSF18] to induce a stronger T cell activation are currently being evaluated in early-phase clinical trials for patients with metastatic melanoma and other solid tumors (5, 6) . Although the intrinsic properties of each Ab and the selection of the appropriate indications for use play an important role in the clinical outcome, emerging data from a small clinical study reported limited clinical activity for anti-GITR monotherapy and potentially promising data for the combination therapy (7) . In preclinical studies in which monotherapy with anti-GITR or anti-PD-1 Ab has limited efficacy (e.g., in large or poorly immunogenic murine tumors) (6, 8) , combination therapy was able to achieve long-term survival in mouse models of ovarian and breast cancer (9) . However, the effect of this synergism on T cell dysfunction and the underlying molecular mechanisms remain unknown. Here, we sought to establish an experimental approach to identify the mechanisms of antitumor synergism between anti-GITR and anti-PD-1 Abs. We genetically profiled more than 2000 tumor-infiltrating CD8 + T cells in the murine MC38 colon adenocarcinoma model using single-cell T cell receptor (TCR) and transcriptome sequencing. Our systematic approach demonstrated that combination immunotherapy rescued T cell dysfunction while promoting a memory phenotype and also revealed the molecular pathways driving durable antitumor responses in the MC38 and RENCA tumor models. Identification of these pathways provides a rational basis for optimizing existing combination immunotherapies and improving tumor responsiveness.
in established tumors (8, 11, 12) . To determine the relative contribution of GITR agonism, we selected the DTA-1 mouse IgG2b isotype in this model to avoid maximum regulatory T cell (T reg ) depletion as seen with the mouse IgG2a isotype, allowing us to test the effect of the combination therapy. The Abs were administered on 6 and 13 days after tumor challenge when tumors were palpable. In line with previous studies (9, 12, 13) , whereas anti-GITR or anti-PD-1 treatment alone exhibited little antitumor effect, combination therapy synergistically prolonged overall survival time of mice (~70% of mice were tumor free for >80 days; Fig. 1A ). Cell depletion studies showed that tumor rejection was primarily dependent on the CD8 + T cells, because removal of CD8 + T cells abrogated the antitumor effect elicited by anti-PD-1/GITR Ab treatment (Fig. 1B and fig. S1 ). The antitumor effect was associated with a reduction in intratumoral T reg and a robust increase in the effector CD8 + and CD4 + T cell (T Eff )-to-T reg ratio, indicating a more immunostimulatory microenvironment (Fig. 1 , C and D) and validating previous findings by other groups (13, 14) . In addition, combination therapy increased proliferation (as judged by expression of Ki67) and granzyme A and B production by intratumoral CD8 + T cells ( Fig. 1 , E to G).
Concurrent single-cell TCR and transcriptome analyses identified a unique gene signature of clonally expanded CD8 + T cells upon combination immunotherapy
We developed and validated a new bioinformatics platform designated rpsTCR (for random priming sequencing TCR) to extract, reconstruct, and analyze TCR sequences after single-agent or combination treatment. Briefly, this platform uses random priming RNA sequencing (RNA-seq) data generated from sorted single cells to identify mouse T cell clones potentially associated with tumor reactivity across different treatments ( fig. S2 and table S2) (15) . Mice were treated as described in Fig. 1 , and more than 2000 CD8 + T cells were sorted from tumor-bearing mice at days 8 and 11 after tumor challenge ( Fig. 2A) . The rpsTCR platform was used to profile the TCR sequences of 1379 + T cell/T reg and CD4 + T Eff /T reg ratio on days 8 and 11 after tumor challenge. Data are representative of three independent experiments (n = 7 mice per group). (E to G) Combination treatment reinvigorates intratumoral dysfunctional T cells. Tumors were harvested on days 11 and 12 after implantation, dissociated into single-cell suspension restimulated with phorbol 12-myristate 13-acetate/ionomycin with the presence of brefeldin A. Cells were fixed and permeabilized, followed by intracellular staining with Ki67 (E), granzyme A (F), and granzyme B (G). Data shown are percentages of positive cells (n = 8 to 9 mice per group). All error bars in figures show SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, log-rank test (A) and one-way ANOVA with Tukey's test (C to G).
CD8 + T cells. Our detection rates of TCRB-CDR3 (86%), TCRA-CDR3 (78.2%), and paired TCRB and TCRA (73.1%) were comparable with the reported detection rates using targeted TCR sequencing from single T cells (table S2) (15) . At the early time point (day 8), very few clones of high-frequency T cells (defined as ≥ 3 T cells sharing identical TCR sequences) were detected in all treatment groups ( fig. S3) . By day 11, we identified two high-frequency T cell clones (representing 5.7% of sequenced single CD8 + T cells) from isotype control samples-3 clones (20.3%) for anti-GITR samples and 6 clones (26.7%) for anti-PD-1 samples-and 10 clones (31.9%) for combination-treated samples. Between days 8 and 11, a significant clonal expansion of intratumoral CD8 + T cells was induced by anti-PD-1 monotherapy, in agreement with published data on human melanoma patients (16) showing an increase in TCR clonal size after anti-PD-1 therapy with pembrolizumab. Our results extend these findings by showing that dual targeting of PD-1 and GITR further enhances intratumoral CD8 + T cell TCR clonal expansion ( fig. S3 ). Of note, anti-GITR and/or anti-PD-1 had no significant impact on peripheral (spleen) T cell clonality ( fig. S3 ), consistent with patient data using pembrolizumab (16). To evaluate the effect of combination therapy on the activation state of intratumoral CD8 + T cells, we performed gene expression pathway analysis on clonally expanded CD8 + T cells. Combination treatment synergistically integrated the pathways modulated by each single agent, resulting in a distinct transcriptional state associated with induction of adaptive immune response, cell cycle, and metabolic activity gene expression pathways (Table 1) . We then applied to our data the uncoupled T cell dysfunction and activation gene expression module analysis, as described by Singer et al. (17) . A total of 452 genes were significantly regulated by either single-agent or combination treatment compared with isotype control. These genes were plotted against the activation/dysfunctional score ( Fig. 2B , P < 0.05). Genes shared or unique across treatment groups were sorted on the basis of P value and then grouped into six clusters (Fig. 2C) . Selected genes differentially increased in each group and fold changes compared with isotype control treatment are listed in table S3. Up-regulation of certain T cell activation markers (i.e., IL2rb) was shared across treatment groups, whereas most of the differentially regulated gene signatures were nonoverlapping, consistent with distinct transcriptional states of expanded CD8 + T cell clones. GITR agonism specifically up-regulated genes involved in T cell activation/cytotoxicity (Il2ra, Txk, Gzme, Gzmd, and Prf1), in prosurvival function (Tnfrsf1b), and in immune checkpoint (Havcr2, Tigit, and Entpd1). PD-1 blockade stimulated induction of Gata3, Tox, Mt2, and Pdcd4 (18) , which are involved in T cell dysfunction and apoptosis, and promoted expression of Themis assisting TCR signaling to low-affinity ligands (19) . Cd226, a costimulatory molecule that plays an important role in antitumor response (20) , was the most up-regulated gene upon combination therapy, followed by other genes involved in signal transduction and T cell differentiation/activation (Pde4d, Vav1, Mki67, and Id2) (21) (22) (23) . Furthermore, combination treatment, in contrast to monotherapy, selectively prevented the up-regulation of genes involved in T cell differentiation/dysfunction, such as Eomes, Mt1, Mt2, and Cd200.
This activation and dysfunctional module score allowed us to quantitatively compare the complex T cell activation profile among different treatment groups. The activation module had significantly higher scores in the combination versus monotherapy treatment groups, indicative of a more activated T cell state [ Fig. 2D ; Kolmogorov-Smirnov (KS) test, P < 0.05].
Overall, although single-agent therapy expanded intratumoral CD8 + T cell clones and modulated critical gene pathways, this was not sufficient for complete and long-lasting tumor rejection (Fig. 1A) . Our findings suggest that a profound reprogramming of dysfunctional tumorinfiltrating T cells by combination therapy was required for tumor rejection and long-term response. This result is supported by a recent study showing that CD8 + T cells quickly become dysfunctional at early stage of tumor development and gradually evolve into a less flexible state (24) .
Anti-PD-1 and anti-GITR combination therapy modulates distinct tumor-specific CD8
+ T cell populations To determine whether distinct cellular mechanisms underlie anti-PD-1-and anti-GITR-mediated tumor rejection, we profiled tumorinfiltrating T cells by high-dimensional flow cytometry and used well-validated data-driven unsupervised clustering approaches (25, 26) . Our attempt to use published mutated MC38 tumor epitopes (27) to track MC38-specific T cell clones was not successful. This possibly reflects the different mutation status of tumor cell lines between laboratories, likely due to intrinsic genome instability of the tumor cells (28) .
As an alternative approach, we generated MC38 tumor cell variant expressing H-2K b single-chain trimer of major histocompatibility complex class I with SIINFEKL peptide (as a surrogate tumor epitope) and Next, we profiled T cells from tumor-bearing mice treated with anti-GITR and/or anti-PD-1 Ab using T cell differentiation/activation markers (e.g., PD-1, TIM3, LAG3, KLRG1, CD244, and CD44) and T cell lineage transcription factors (e.g., Eomes and Tbet). We detected heterogeneity within the Ag-specific CD8 + T cells, reflecting different activation/differentiation states ( Fig. 3A) . At day 9, T cell populations between treatment groups were indistinguishable; however, a marked skew in the population was observed by day 12 in response to anti-GITR Ab alone or combination treatment (Fig. 3B ). To gain a more comprehensive understanding of the phenotypes of the T cell populations that were affected by the treatment, we analyzed Ag-specific CD8 + T cells using unsupervised spanning-tree progression analysis of density-normalized events (SPADE) clustering. Fourteen distinct Agspecific CD8 T cell clusters (>2% relative frequency) were identified (Fig. 3C ). Among them, clusters 14, 12, and 7 were highly responsive to anti-GITR and anti-PD-1 treatment (Fig. 3D ). On the basis of the high expression level of T cell activation/dysfunction markers (PD-1, Table 1 . Pathways specifically up-regulated in clonal expanded CD8 + T cells with Ab treatment (day 11). Genes specifically up-regulated in monotherapy or combination therapy compared with isotype control were analyzed using Illumina Gene Ontology Engine. Jak, Janus kinase; STAT, signal transducers and activators of transcription. TIM3, LAG3, CD244, Eomes, Tbet, and KLRG1), these three clusters likely represent different stages of dysfunction ( Fig. 3E and fig.  S5 ), unlike cluster 10 representing a more naïve/quiescent phenotype. Cluster 14 is absent at the earlier time point and has the highest expression level of markers associated with dysfunctional T cells, suggesting a terminal stage of dysfunction. All treatment groups were associated with a relative decrease in dysfunctional T cell frequency, and there was no significant difference between treatment groups (Fig. 3D) Fig. 3 , F and G).
Treatment
To further characterize the responsive T cell populations, we used additional differentiation and activation markers to phenotypically dissect the T cells (e.g., Sca1, CD95, CD127, CD122, CD226, and Ki67). Unique cell populations can be identified upon treatment on day 12 (Fig. 4, A and B, and fig. S6 ). SPADE clustering was conducted using this specific panel of markers (Fig. 4C) to allow for statistical analysis between groups for a single cluster. We observed a specific effect of the combination treatment that was driven primarily by the anti-GITR Ab in expanding a unique memory cell population (cluster 11; Fig. 4 , C to F) that may confer long-lasting protective immunity. These cells express CD62L and CD44 (Fig. 4E) , similar to memory cells in the spleen compartment, while up-regulating additional key markers (Sca1, CD95, CD127, CD122, and Eomes), characteristic of a memory precursor effector cell phenotype (MPEC) as previously described (29) (Fig. 4F) . Overall, combination therapy drives the expansion of MPECs, which represent a very small fraction of CD8 and become functional memory T cells, which are essential to confer protective immunity (3). These cells also express high levels of CD226 and Ki67, suggesting an activated and highly proliferative state (Fig. 4F) . Further, these intratumoral OVA-specific CD8 + T cells from cluster 11 showed increased IFN-, and granzyme B production upon Ag-specific restimulation followed single-agent treatment, but only combination treatment significantly enhanced their function (Fig. 4G) .
In agreement with previous findings, we showed that although anti-PD-1 alone induces a less dysfunctional tumor-infiltrating lymphocyte (TIL) phenotype (Fig. 3) , it is associated with low T EMs (30, 31) and lack of long-term survival ( Fig. 1) (32) . We demonstrated that combination therapy can promote a memory CD8 + T cell phenotype, indicating that a costimulatory agonist Ab can synergize with PD-1 checkpoint blockade, leading to long-term antitumor responses. We further investigated the mechanism by which this specific combination therapy effect occurred by functional analysis of the identified upregulated genes.
CD226 expression is induced on tumor-specific CD8
+ T cells upon combination therapy CD226, a costimulatory molecule with a well-validated role in the development of antitumoral immune response (31) , was identified as the most up-regulated gene upon combination therapy (Fig. 1, B and C, and table S3). We performed a Cd226 expression analysis on different subsets of intratumoral CD8 + T cells (total, clonally expanded, or nonexpanded) across treatment groups (Fig. 5A) , which revealed that Cd226 mRNA levels were significantly increased by combination treatment on clonally expanded T cells (fold change, 10.7), whereas this difference was diluted in bulk/total CD8 + T cells (fold change, 3.5) and nonexpanded CD8 + T cells (not significant). Further, Cd226 mRNA levels were significantly increased by combination treatment on clonally expanded CD8 + T cells in comparison to anti-PD-1 (fold change, 6.5) and anti-GITR (fold change, 9.2). Using the MC38-OVA- 2 m-K b model, we found that protein levels of CD226 were highest on spleen OVA-specific CD8 + T cells after anti-PD-1 treatment (Fig. 5B ) and were further elevated by combination treatment. The same treatment had no significant effect on the CD226 levels of nonspecific CD8 + T cells. This dataset suggests that anti-PD-1 treatment could play a dominant role in driving the increase of CD226 on Ag-specific T cells, providing key information on the mode of action of anti-PD-1 in antitumor immunity.
CD226 is a substrate for dephosphorylation by PD-1-SHP2
Next, we investigated a potential association between PD-1 signaling and CD226. The costimulatory receptor CD28 was previously identified as a target for PD-1-SHP2 dephosphorylation (32) . Experiments using a cell-free reconstitution system in which the cytoplasmic domain of PD-1 was bound to the surface of large unilamellar vesicles (LUVs) that mimic the plasma membrane of T cells demonstrated that CD28 is preferred over the TCR as a target for SHP2-mediated dephosphorylation. Using the same system, we examined whether CD226 could be another target for dephosphorylation by the PD-1-SHP2 complex.
We reconstituted different components (CD3, CD226, etc.) involved in T cell signaling on the liposomes (Fig. 5C ) (33) . The sensitivity of each component in response to PD-1 titration on the LUVs was measured by phosphotyrosine (pY) Western blots. We confirmed previous published data (32) showing that CD28, but not inducible T cell costimulator (ICOS), is a substrate for desphosphorylation by PD-1-SHP2 (Fig. 5D) . We found that CD226 was efficiently dephosphorylated by PD-1-SHP2 in a dose-dependent manner (Fig. 5D ) in the presence of LFA-1. Although LFA-1 facilitates T cell activation by lowering the amounts of antigen necessary for T cell activation (33), cross-linking of LFA-1 induces tyrosine phosphorylation of DNAM-1 (CD226) (34) .
Although additional experiments are needed to fully characterize the basis of CD226 sensitivity to PD-1-SHP2-induced dephosphorylation, we demonstrated a biochemical association between PD-1 signaling and CD226 dephosphorylation using a cell-free biochemical system. To validate these findings in a more physiologically relevant system involving primary cells from the tumor microenvironment, we isolated Ag-specific intratumoral CD8 + T cells from MC38-OVA tumorbearing mice (day 11) previously treated with anti-PD-1 Ab or isotype control Ab. Consistent with the cell-free in vitro assay, we found that CD8 + TILs from the PD-1 Ab-treated group showed high CD226 phosphoryl ation upon PD-1 inhibition (Fig. 5E) , confirming that CD226 is in an activated state. CD8 + TILs from isotype control-treated mice showed a lack of CD226 phosphorylation, indicating that PD-1/PD-L1 pathway is a negative regulator of CD226 activity on intratumoral CD8 + T cells. These data suggest that CD226 is an additional substrate for dephosphorylation by PD-1-SHP2.
Down-regulation of TIGIT expression upon GITR Ab treatment shifts the CD226/TIGIT pathway toward stronger costimulation
It has recently been shown that the strength of CD8 + T cell response is affected by the overall balance between CD226 and the coinhibitory receptor TIGIT (31) . Single-cell RNA-seq data indicated that anti-GITR Ab treatment increased TIGIT transcripts in high-frequency T cell clones ( fig. S7A ), whereas FACS analysis showed lower expression of TIGIT on OVA-specific CD8 + T cells with anti-GITR or combination treatment compared with anti-PD-1 treatment alone ( fig. S7B ). This result is consistent with the observation that TIGIT expression is tightly regulated at the posttranscriptional level (35) . . S7F ) on the dysfunctional T cell cluster 14 (identified in Fig. 3D ) is uniformly high (~100%), whereas the memory-like T cell cluster 11 (identified in Fig. 4D ) shows much lower levels of TIGIT expression. In addition, because GITR is highly expressed on T regs , we performed a comprehensive profiling [t-distributed stochastic neighbor embedding (t-SNE)-based visualization (viSNE)/SPADE] analysis on the remaining intratumoral T regs upon combination treatment and compared the results to a well-studied T reg -depleting Ab (anti-CD25, PC61). We found that GITR and PD-1 combination therapy has a distinct effect on the phenotype of the remaining T regs compared with the anti-CD25 Ab treatment group. GITR and PD-1 combination treatment skewed the remaining T reg subsets toward a less suppressive phenotype, as defined by a lower expression of TIGIT, KLRG1, LAG3, and TIM3 ( fig. S8 ). All these markers have been reported to identify a highly activated and phenotypically suppressive T reg population (36, 37) . To assess whether the distinct effect of GITR and CD25 Abs on T reg depletion could differentially alter the phenotype of CD8 + T cells, we analyzed the intratumoral OVA-specific CD8 + T cells ( fig. S9 ). Using an extended 18-parameter viSNE analysis, we found that GITR and PD-1, but not CD25 and PD-1, combination Ab treatment significantly decreased the dysfunctional phenotype (cluster 1: low Ki67, CD226, Sca1, CD95, CD122, high KLRG1, PD-1, LAG3, and CD244) and the naïve-like T cells (cluster 10: CD62L + CD44 − , low Ki67, CD226, PD-1, and other T cell activation markers), whereas it increased the cluster with memorylike activated T cell phenotype (cluster 6: high CD226, Ki67, Sca1, CD127, CD95, and CD122 and lower level of PD-1, TIM3, LAG3, KLRG1, and CD244). These data show that the shift in balance between CD226 and TIGIT is driven by the direct combination of PD-1 and GITR Abs and not solely through a reduction in intratumoral T regs ( fig. S9, E and F) .
Overall, the single-cell RNA-seq and FACS phenotyping data showed that anti-PD-1 favored the increased expression of CD226, whereas anti-GITR treatment down-regulated surface expression of TIGIT and reduced intratumoral T reg subsets with a highly suppressive phenotype, therefore synergistically restoring the homeostatic CD8 + T cell function.
CD226 signaling pathway is essential in mediating the antitumor response induced by combination treatment
Using a CD226-blocking monoclonal Ab, we showed that costimulatory signaling through CD226 is required for the antitumor immunity mediated by combination treatment (Fig. 5F ). To validate the T cell intrinsic role of CD226, we genetically inactivated it in C57BL/6 background mice ( fig. S10, A (fig. S10F ). After tumor challenge in the CD226 KO mice, we found that combination treatment with anti-PD-1 and anti-GITR no longer conferred any antitumor effect or survival benefit, suggesting that CD226 is essential for the antitumor effect of the combination therapy (Fig. 5G ). In addition, we validated the specificity of the CD226 pathway mediating this effect because inhibition of TNFR superfamily pathways (OX40/OX40L or 4-1BB/4-1BBL) or blockade of the B7 costimulatory molecule (CD28) with CTLA4-Ig had no impact on the antitumor effect observed with the combination treatment ( fig. S11 , A to C). In mice lacking CD226, combination therapy can no longer maintain the activated and highly proliferative memory T cell phenotype (PD-1 (Fig. 5, H and I) .
To test whether the mechanisms found in the MC38 model also extend to other tumor cell models, we evaluated the role of PD-1 and GITR combination therapy in the RENCA tumor model (murine kidney carcinoma tumor in Balb/c background). This tumor cell line was chosen because it also showed relatively good expression of CD155, the endogenous ligand for CD226 ( fig. S12 ). Consist ent with the MC38 studies, anti-GITR and anti-PD-1 combination therapy can synergize and promote long-term survival of RENCA tumorbearing mice (Fig. 6A) . FACS analysis of tumor-infiltrating T cells revealed a significant reduction in T reg driven by GITR Ab and expansion of tumor-specific CD8 + T cells (gp70-tetramer + ) driven primarily by PD-1 Ab (Fig. 6, B and C) . In addition, we also observed a significant increase of CD226 expression on tumor-specific CD8 + T cells (Fig. 6D, gp70 tetramer + cells), consistent with our observations in the MC38 tumor model. viSNE and SPADE analyses (Fig. 6 , E to G) revealed an increase in memory-like effector cell cluster (Fig. 6G, C5 ; high CD95, CD122, Ki67, and Tbet and low CD44 and TIM3) accompanied by reduced dysfunctional T cell cluster (Fig. 6G, C1 ; high TIM3 and low Ki67, CD95, CD122, Tbet, and Sca1). Likewise, when CD226 signaling is blocked by an anti-CD226 Ab during combination treatment, the antitumor efficacy is completely abrogated (Fig. 6I) , as previously demonstrated in the MC38 tumor model. Thus, our data provide additional evidence that the role of CD226 is not limited to one tumor model or mouse genetic background.
DISCUSSION
We systematically profiled tumor-infiltrating CD8 + T cells using single-cell TCR sequencing, transcriptomics, and high-dimensional flow cytometry clustering analysis to unveil the molecular mechanisms driving the potent synergism of a costimulatory agonist, anti-GITR Ab, and a coinhibitory antagonist, anti-PD-1 Ab. We showed that a combination of these Abs synergistically enhanced the effector function of expanded CD8 + T cells by restoring the balance of two key homeostatic regulators, CD226 and TIGIT, resulting in robust survival benefit.
Recently, it has been shown that T cell dysfunction represents an important hurdle for the generation of durable responses upon PD-1 inhibition (3). PD-1 blockade induces an incomplete rescue of T Ex , thus failing to restore T Ex into T EM , a necessary requirement for effective immune memory (38, 39) . We demonstrated that combination therapy not only decreased the intratumoral CD8 + T cells with a nonprogrammable dysfunctional profile (Fig. 3, F and G) (31, 40) but also induced a highly proliferative TEM precursor population (Fig. 4) (32, 41) , thus eliciting potent antitumor immunity in a CD226-dependent manner (Figs. 5, F and G, and 6I) . The similarity in the efficacy between both MC38 and RENCA tumor models despite different mouse genetic backgrounds and tumor types (C57BL /6 and Balb/c; colon and kidney adenocarcinoma, respectively) suggests that this mechanism is not limited to a specific tumor model. However, further research is needed to determine whether the reduction of dysfunctional CD8 + T cells is through the reinvigoration of these populations and/or epigenetic reprogramming of them into a functional state (24) .
Furthermore, we validated our findings using gene pathway analysis to show that although anti-GITR and anti-PD-1 monotherapies regulated distinct molecular pathways, combination treatment synergistically integrated the pathways modulated by each single agent, resulting in a distinct transcriptional state of CD8 + T cells (Table 1 ). In addition, applying to our data the uncoupled T cell dysfunction and activation gene expression module score, as described by Singer et al. (17) , enabled us to quantitatively compare the complex T cell activation profile between different treatment groups. We found that the activation module had significantly higher scores in the combination versus monotherapy treatments groups, indicative of a more activated T cell state (Fig. 2, B to D) . Last, we confirmed CD226 as the most up-regulated gene upon combination treatment. We developed a new bioinformatic pipeline rpsTCR that allowed us to selectively profile clonally expanded intratumoral CD8 + T cells, which displayed distinct gene signature upon treatment with anti-PD-1 and/or anti-GITR Ab. Expression analysis of different subsets of intratumoral CD8 + T cells (total, clonally expanded, or nonexpanded) across treatment groups revealed that CD226 mRNA level was significantly increased by combination treatment in clonally expanded T cells, although this difference was diluted and lost in bulk and nonexpanded CD8 + T cells. This observation stresses the importance of performing genome profiling on putative tumor-reactive clones (high-frequency T cell clones) to unmask critical gene changes. These genetic findings were validated at the protein level by comparing cell surface CD226 expression on tetramer-positive, antigen-specific intratumoral CD8 + T cells after different Ab treatments. One potential limitation of the MC38 tumor model is that we tracked the clo nally expanded CD8 + T cells using a surrogate OVA antigen due to lack of reagents to track endogenous tumor antigen-specific CD8 + T cells. However, we were able to validate the findings using the RENCA tumor model and endogenous tumor antigen-specific T cells. Recently, both cis-and trans-inhibitory mechanisms have been proposed for the TIGIT/CD226 signaling pathway (31) . Therefore, the net output of this pathway may result from the balance between the expression level of CD226 on CD8 + T cells and TIGIT on both CD8 + T cells and bystander lymphocytes. We found CD226 as a previously unidentified target for PD-1-initiated SHP2 dephosphorylation (Fig. 7) in addition to CD28 (32) , thus revealing additional complexity of the PD-1 pathway. In addition, we showed that PD-1 blockade rescued CD226 dephosphorylation by PD-1-SHP2, whereas GITR agonism reduced TIGIT expression, which competes for CD155/PRV binding with CD226 (42) . Therefore, only the combination treatment restored T cell effector function by favorably tipping the balance between CD226 and TIGIT leading to durable antitumor responses (model shown in Fig. 7) .
In summary, the systematic approaches used in this study can shed light on important functional T cell regulatory pathways implicated in the synergy between two immunotherapeutic Abs, representing distinct immunotherapeutic modalities (costimulatory agonism and 
MATERIALS AND METHODS

Study design
The aim of this study was to dissect the molecular and cellular mechanisms mediated by combination immunotherapy. Single-cell RNA-seq analysis study of tumor-infiltrating CD8 + T cells was designed to identify the specific gene signature induced upon treatment. Single-cell suspensions were profiled by high-dimensional computational flow cytometry to identify phenotypic changes in cell populations. To validate our findings, we designed in vitro biochemistry experiments and additional in vivo studies using either genetically engineered mice or blocking Abs. Control and experimental treatments were administrated to age-and sex-matched mice. Investigators were blinded for tumor measurements. The number of experimental replicates is indicated in the figure legends.
Mice and treatments
Six-to eight-week-old female C57BL/6 and Balb/c mice were obtained from the Jackson laboratory. CD226 −/− mice on a C57BL/6 background were generated at Regeneron Pharmaceuticals Inc. using the VelociGene method (43, 44) . Briefly, enhanced green fluorescent protein complementary DNA (cDNA) was inserted in-frame to the start codon, followed by a selection cassette that disrupts transcription of the gene body and results in a CD226 null allele. Heterozygous targeted mice were interbred to produce homozygous KO mice for study. All animals were maintained under pathogen-free conditions, and experiments were performed according to protocols approved by the Institute of Animal Care and Use Committee of Regeneron Pharmaceuticals Inc. For tumor studies, 3 × 10 5 MC38 or 1 × 10 6 RENCA cells were subcutaneously injected on the right flank of age-matched C57BL/6 or Balb/c, respectively. Six days after tumor implantation, mice (randomly distributed in different groups) were grouped on the basis of tumor size and treated by intraperitoneal injection with anti-GITR (5 mg/kg; DTA-1) and/or anti-PD-1 (RPM1-14) Ab or isotype control IgGs (rat IgG2b, LTF-2 and rat IgG2a, 2A3; Bio X Cell). Abs were administered again on day 13. Depletion/blocking Abs were given 1 to 2 days before immunotherapy. Perpendicular tumor diameters were measured blindly two to three times weekly using digital calipers (VWR, Radnor, PA). Volume was calculated using the formula L × W × W × 0.5, where L is the longest dimension and W is the perpendicular dimension.
Flow cytometry
For flow cytometry analysis of in vivo experiments, blood, spleen, thymus, lymph node, and tumor were harvested on indicated days after treatment. Single-cell suspensions were prepared, and red blood cells were lysed using ACK lysis buffer (Thermo Fisher Scientific). Live/dead cell discrimination was performed using Live/Dead Fixable Blue Dead Cell Staining Kit (Thermo Fisher Scientific). Ag-specific CD8 + T cells were detected with H-2K b /OVA SIINFEKL-Pentamer (ProImmune) for MC38-OVA model and H-2L d /MuLV gp70-SPSYVYHQF tetramer (MBL International) for RENCA model. For intracellular cytokine staining, cells were stimulated with or without SIINFEKL peptide for 36 hours and with a protein transport inhibitor (BD Biosciences) for the last 4 hours. After stimulation, cells were stained as described above for surface and intracellular proteins.
To quantify cell numbers in tissue, a fixed number of CountBright absolute counting beads (Thermo Fisher Scientific) were added to each sample before acquiring. Samples were acquired on LSRFortessa X-20, LSR II, or Symphony (BD Biosciences) and analyzed using FlowJo (TreeStar) and Cytobank. Further details are in Supplementary Materials and Methods.
Single-cell sorting RNA-seq FACS-sorted tumor and spleen CD8 + T cells were mixed with C1 cell suspension reagent (Fluidigm) before loading onto a 5-to 10-m C1 integrated fluidic circuit (Fluidigm). Cell lysing, reverse transcription, and cDNA amplification were performed on the C1 Single-Cell Auto Prep Integrated Fluidic Circuit, as specified by the manufacturer (protocol 100-7168 E1). The SMARTer Ultra Low RNA Kit (Clontech) was used for cDNA synthesis from the single cells. Illumina next-generation sequencing libraries were constructed using the Nextera XT DNA Sample Prep Kit (Illumina). Cells were sequenced on Illumina NextSeq (Illumina) by multiplexed single-read run with 75 cycles. Raw sequence data (BCL files) were converted to FASTQ format via Illumina Casava 1.8.2. Reads were decoded on the basis of their barcodes. Read quality was evaluated using FastQC (www.bioinformatics.babraham.ac.uk/projects/fastqc/). Further details are in Supplementary Materials and Methods.
LUV reconstitution and phosphotyrosine Western blot
LUVs reconstituted different components (ICOS, CD28, and CD226) involved in T cell signaling on the liposomes, together with LCK, ZAP70, SLP76, and PI3K as previously described (45) (46) (47) . Proteins of interest were premixed at desired ratios in 1× reaction buffer containing bovine serum albumin (0.5 mg/ml) and then mixed with LUVs (1 mM total lipids) as described previously (32) . Fifty micrograms of protein for each sample was used for the Western blot. Further details are in Supplementary Materials and Methods.
Statistical analysis
Sample sizes were chosen empirically to ensure adequate statistical power and were in the line with field standards for the techniques used in the study. Statistical significance was determined with analysis of variance (ANOVA) or unpaired two-tailed Student's t test, assuming unequal variance at P < 0.05 level of significance (or indicated in figure legends).
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